FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients

Abstract

FOLFOX-4 is an effective and well-tolerated regimen as a second-line treatment in advanced gall bladder cancer patients. Further studies are required, especially in the Indian subcontinent.

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

“…Both best supportive care alone (BSC) and BSC + 2LCTX are practicable options in the second-line setting 11 , but considerable uncertainty exists to date about which of these two treatment approaches will benefit patients most. Observational evidence in support of the 2LCTX + BSC approach is based on retrospective cohort studies of aBTC patients treated with fluoropyrimidine-based mono- or polychemotherapy 10–18 . However, due to their single-arm design, these studies cannot address the overall benefit of 2LCTX over BSC.…”

A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study

“…Although GC has created the basis as first line treatment choice, after tumors progress, there are no standard secondary or later line therapies. Fluoropyrimidine-based combination therapy with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) showed a median PFS of 1.6-3.9 months and a median OS of 4.4-8.4 months [37,38]. The most recently published results from ABC-06, which was an open-label, phase III trial comparing 12 cycles of mFOLFOX plus active symptom control (ASC) with ASC alone in the second line setting, the RR was 5% and the median PFS was 4.0 months in the ASC plus FOLFOX group.…”

The Synergistic Effect of Canady Helios Cold Atmospheric Plasma and A Folfirinox Regimen for The Treatment of Cholangiocarcinoma In Vitro

“…The early issues in these studies are toxicity of FOLFIRINOX and early triumphs show that the regimen can be safe in patients who are able to tolerate it. These trials attempt to minimize toxicities by reducing or modifying drug doses because patients are excluded due to low performance status 13,35 .…”

“…Dosage iterations of modi ed FOLFOX-4, FOLFOX-5, and FOLFOX-7 have been used to treat pancreatic, colorectal, and bladder cancers [13][14][15] .…”